The deposition of abnormal tau protein is a hallmark for a large group of human cognitive disorders (tauopathies), which includes Alzheimer’s disease [1, 2], several forms of parkinsonism [3] or frontotemporal lobar degeneration (FTLD)—such as corticobasal degeneration, progressive supranuclear palsy, inherited frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)—among others [4–6]. Here, MAPT is linked to tauopathy.